Multifaceted Cannabinoids: Regulators of Normal and Pathological Function in Metabolic and Endocrine Organs

36.5K
views
39
authors
8
articles
Cover image for research topic "Multifaceted Cannabinoids: Regulators of Normal and Pathological Function in Metabolic and Endocrine Organs"
Editors
3
Impact
Loading...
4,566 views
15 citations
5,389 views
15 citations
Review
07 July 2021

Chronic kidney disease (CKD) concerns millions of individuals worldwide, with few therapeutic strategies available to date. Recent evidence suggests that the endocannabinoid system (ECS) could be a new therapeutic target to prevent CKD. ECS combines receptors, cannabinoid receptor type 1 (CB1R) and type 2 (CB2R), and ligands. The most prominent receptor within the kidney is CB1R, its endogenous local ligands being anandamide and 2-arachidonoylglycerol. Therefore, the present review focuses on the therapeutic potential of CB1R and not CB2R. In the normal kidney, CB1R is expressed in many cell types, especially in the vasculature where it contributes to the regulation of renal hemodynamics. CB1R could also participate to water and sodium balance and to blood pressure regulation but its precise role remains to decipher. CB1R promotes renal fibrosis in both metabolic and non-metabolic nephropathies. In metabolic syndrome, obesity and diabetes, CB1R inhibition not only improves metabolic parameters, but also exerts a direct role in preventing renal fibrosis. In non-metabolic nephropathies, its inhibition reduces the development of renal fibrosis. There is a growing interest of the industry to develop new CB1R antagonists without central nervous side-effects. Experimental data on renal fibrosis are encouraging and some molecules are currently under early-stage clinical phases (phases I and IIa studies). In the present review, we will first describe the role of the endocannabinoid receptors, especially CB1R, in renal physiology. We will next explore the role of endocannabinoid receptors in both metabolic and non-metabolic CKD and renal fibrosis. Finally, we will discuss the therapeutic potential of CB1R inhibition using the new pharmacological approaches. Overall, the new pharmacological blockers of CB1R could provide an additional therapeutic toolbox in the management of CKD and renal fibrosis from both metabolic and non-metabolic origin.

6,852 views
25 citations
6,323 views
23 citations
Open for submission
Frontiers Logo

Frontiers in Endocrinology

Unraveling Immune Metabolism: Single-Cell & Spatial Transcriptomics Illuminate Disease Dynamics
Edited by Yejun Tan, Zhengtao Liu, Yafeng Zhu
Deadline
03 June 2025
Submit a paper
Recommended Research Topics
Frontiers Logo

Frontiers in Physiology

The Endocrine Regulation of Systemic Energy Homeostasis under Physiological and Pathological Conditions
Edited by Hui-Ying Lim, Weidong Wang, Yoshimi Nakagawa, Krystyna Pierzchała-Koziec
113.5K
views
39
authors
9
articles
Frontiers Logo

Frontiers in Endocrinology

The Impact of Adipose Tissue Dysfunction on Cardiovascular and Renal Disease
Edited by Xiaodong Sun, Alexandre A. da Silva, Cheng-Chao Ruan
76.6K
views
84
authors
11
articles
Frontiers Logo

Frontiers in Endocrinology

The Impact of Adipose Tissue Dysfunction on Cardiovascular and Renal Disease, Volume II
Edited by Xiaodong Sun, Alexandre A. da Silva, Cheng-Chao Ruan
54.9K
views
89
authors
12
articles
Frontiers Logo

Frontiers in Endocrinology

Multifaceted Cannabinoids: Regulators of Normal and Pathological Function in Metabolic and Endocrine Organs, volume II
Edited by Rosaria Meccariello, Antonietta Santoro, Kanikkai Raja Aseer, Morvarid Kabir
43.1K
views
29
authors
5
articles
Frontiers Logo

Frontiers in Endocrinology

Redox Signaling and Homeostasis in the Control of Metabolism: A Systemic Interplay Between Central and Peripheral Effectors
Edited by Letizia Palomba, Elena Silvestri, Cristoforo Silvestri
22.8K
views
33
authors
6
articles